The medication may represent a new treatment option for dialysis patients, researchers concluded.
Soluble ferric pyrophosphate is given to hemodialysis patients via dialysate.
Levels below 10 g/dL found to increase risk of a composite endpoint of all-cause mortality, cerebrovascular events, and myocardial infarction.
Over 52 weeks, the drug maintained hemoglobin levels while decreasing IV iron use in dialysis patients with anemia.
Benefit seen among anemia and hemodialysis patients with hemoglobin levels below 10 g/dL.
Renal events are significantly less likely if erythropoiesis-stimulating agents are started at hemoglobin levels below 11 g/dL.
New finding on vitamin B6 is the opposite of what investigators hypothesized on patients with anemia.
IV iron in anemia hemodialysis patients hospitalized for bacterial infections found not to worsen outcomes.
Use of erythropoiesis-stimulating agents in anemia patients decreased, while use of iron increased.
Hemoglobin level below 8 mg/dL associated with 82% increased odds of prolonged bleeding time with anemia.
Highest quintile of hemoglobin associated with 6-fold increased odds of complete or partial recovery of anemia in acute kidney injury (AKI).
Researchers believe nocturnal home hemodialysis (NHHD) performed every other night may be superior to NHHD performed 6 or 7 times a week.
Hemodialysis patients with a higher percentage of fat tissue respond better to erythropoiesis-stimulating agents.
Low hemoglobin levels increase the risk of death, sepsis, and cerebrovascular accidents following cardiac surgery.
Doses higher than 70 μg per week were associated with a 77% greater risk of cancer compared with non-use of the agents.
It also was associated with high hemoglobin levels and reduced levels of C-reactive protein.
In 3 trials, the annual cost for preventing 1 patient from being transfused varied from $61,188 to $317,988.
Study reveals a decline in the use of erythropoiesis-stimulating agents and an increase in the use of iron.
Each 0.5 mg/dL increment in phosphorus was associated with a 7% increased risk of anemia.
Ordering process cut the number of epoetin alfa doses by 71% and medication costs by 69%.
In a head-to-head comparison, researchers observed a higher rate of adverse events with iron dextran than iron sucrose or ferric gluconate.
Iron absorbed from oral ferric citrate boosted iron stores and sustained hemoglobin levels.
Patients with higher levels of anti-CMV antibodies have lower number of red blood cells.
CORAL study chair Lance Dworkin, MD, discusses the controversial finding with Renal & Urology News.
Greater resistance to ESA is associated with an increased risk of death among patients on chronic HD.
Considerable variation in incidence of HAA across hospitals; teaching status and region linked to risk.
Serum hepatitis E virus levels were undetectable in 78% of patients at least 6 months after stopping treatment.
Ferumoxytol and iron sucrose have comparable safety in the treatment of anemia in patients with CKD.
Platelets may aggregate more easily in iron-deficient patients.
Soluble ferric pyrophosphate (Triferic), an investigational drug, is delivered to hemodialysis patients via dialysate.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)